Exelixis
EXEL
58.44
+0.11
+0.19%
Exelixis
US · EXEL
#1156 by market cap
Listed 1970
58.44
+0.11
+0.19%
Live - 5344 symbols - heartbeat 435s ago
· 2026-10-08 07:02
Pre-market
58.95
+0.87%
After-hours
58.44
0.00%
Overnight
58.44
0.00%
- Market cap
- 14.48B
- P/E (TTM)i
- 18.38
- P/Bi
- 7.85
- EPSi
- 2.78
- Div yieldi
- 0.00%
- 52W posi
- 90%
Reader sentiment
Are you bullish or bearish on EXEL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.5 percentage points.
Institutional ownership
- Held by institutions
- 106.50% +0.46pp
- Institutions
- 887 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund71.19%
Hedge Fund23.69%
Public Company4.34%
Government Pension Fund2.92%
Individual/Insider2.63%
Private Company2.15%
Sovereign Wealth Fund1.09%
Insurance Company0.54%
Family Office/Trust0.37%
Top holders as of 2026-06-30
BlackRock
11.73% · 29.08M sh
Farallon Capital Management, L.L.C.
5.65% · 13.99M sh
Renaissance Technologies Corp.
5.42% · 13.43M sh
Vanguard Capital Management, LLC
5.06% · 12.54M sh
Vanguard Portfolio Management, LLC
4.86% · 12.04M sh
AQR Capital Management
4.42% · 10.94M sh
State Street Global Advisors
4.02% · 9.97M sh
Fuller & Thaler Asset Management, Inc.
3.60% · 8.93M sh
LSV Asset Management
3.29% · 8.15M sh
Geode Capital Management, LLC
3.09% · 7.65M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Michael Morrissey | Chief Executive Officer | 1.37% |
| Stelios Papadopoulos | Co-Founder & Independent Chair of the Board | 0.48% |
| Christopher Senner | Chief Financial Officer | 0.22% |
| Patrick Haley | Executive Vice President of Commercial | 0.14% |
| Jack Wyszomierski | Independent Director | 0.11% |
| Dana Aftab | Executive VP of Discovery and Translational Research & Chief Scientific Officer | 0.10% |
| Jeffrey Hessekiel | General Counsel | 0.08% |
| George Poste | Independent Director | 0.05% |
| Maria Freire | Independent Director | 0.04% |
| Tomas Heyman | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-09 | Mary Beckerle | Director | Automatic Disposition | -9,812 | $53.66 |
| 2026-05-31 | Jack Wyszomierski | Independent Director | Automatic Disposition | -3,925 | $50.55 |
| 2026-05-31 | Sue Eckhardt | Director | Automatic Disposition | -9,812 | $50.14 |
| 2026-05-26 | Jack Wyszomierski | Independent Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | Stelios Papadopoulos | Co-Founder & Independent Chair of the Board | Other Acquisition | +8,367 | -- |
| 2026-05-26 | George Poste | Independent Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | Sue Eckhardt | Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | Mary Beckerle | Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | Julie Smith | Independent Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | Maria Freire | Independent Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | Robert Oliver | Independent Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | Tomas Heyman | Independent Director | Other Acquisition | +8,367 | -- |
| 2026-05-26 | David Johnson | Independent Director | Other Derivative Acquisition | +19,133 | $50.03 |
| 2026-05-25 | Dana Aftab | Executive VP of Discovery and Translational Research & Chief Scientific Officer | Intent to Sell (Form 144) | -43,451 | $50.35 |
| 2026-05-19 | Patrick Haley | Executive Vice President of Commercial | Open Market Disposition | -32,110 | $49.81 |
| 2026-05-17 | Michael Morrissey | Chief Executive Officer | Other Acquisition | +124,047 | -- |
| 2026-05-17 | Michael Morrissey | Chief Executive Officer | Other Disposition | -124,047 | -- |
| 2026-05-17 | Christopher Senner | Chief Financial Officer | Open Market Disposition | -34,901 | $50.00 |
| 2026-05-17 | Brenda Hefti | General Counsel | Automatic Disposition | -6,625 | $50.21 |
| 2026-05-14 | Michael Morrissey | Chief Executive Officer | Sale to Issuer | -128,497 | $51.10 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:02:37 · For reference only, not investment advice and not tailored to your situation.